Q1 2025 Management View CEO Mark Goldsmith highlighted significant advancements in the company's strategic priorities, particularly in the development of RAS(ON) inhibitors targeting RAS-addicted ...

Learn more about whether Exact Sciences Corporation or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Tumor-treating fields (TTFields) therapy and chemoradiation therapy (CRT) may have significant anti-tumor efficacy in ...

Gossamer Bio's seralutinib shows promise in PAH Phase 2 trials, but Phase 3 success is vital amidst competition. Click to ...

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.

Discover key takeaways from GeoVax Labs' Q1 2025 earnings call, including updates on vaccine trials, the BARDA contract impact, and strategic advancements.

Avacopan has been shown to work well in a real-world setting in a much broader group of people with vasculitis than was studied in the phase 3 trial that led to its approval.

Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...

Compare the leading software options ... Glycomine is proceeding to a six-month placebo-controlled Phase 2b test designed to enroll between 40 and 50 participants age 4 and older.